Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.59 |
| ▸ | GAK | O14976 | 1/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.59 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.59 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.59 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.59 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.59 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.59 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.59 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3358755 | 0.93 | TGFBR1 (0.51) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL413521 | 0.90 | TGFBR1 (0.66) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL409443 | 0.85 | TGFBR1 (0.57) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL4870813 | 0.85 | TGFBR1 (0.62) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL412300 | 0.85 | TGFBR1 (0.70) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL4872102 | 0.84 | TGFBR1 (0.60) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL5233669 | 0.84 | TGFBR1 (0.50) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL4868122 | 0.83 | TGFBR1 (0.57) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL412989 | 0.83 | TGFBR1 (0.47) | TGFBR1MAPK14KDRTGFBR2GAK | |
| SCHEMBL4873429 | 0.83 | TGFBR1 (0.59) | TGFBR1MAPK14KDRTGFBR2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | claimed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | claimed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | claimed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | HOWARD HUGHES MEDICAL INSTITUTE | 2016-04-28 | — | — | US | disclosed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | TGFBR1 3/4885MAPK14 106/4885KDR 849/4885 |
| US-20160115447-A1 | COMPOSITIONS AND METHODS FOR IMPROVING INDUCED NEURON GENERATION | PLK1, GAP43, NEFM | TGFBR1 2217/4885MAPK14 421/4885KDR 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.